Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy

被引：16
|
作者：
Yamashita, Yoriko [1 ]
机构：
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan
来源：
JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 45卷 / 05期
基金：
日本学术振兴会;
关键词：
ovarian clear cell carcinoma; PI3CA mutation; ARID1A mutation; MET amplification; targeted therapy; MALIGNANT-TRANSFORMATION; HISTOLOGICAL SUBTYPES; TUMOR-SUPPRESSOR; PIK3CA GENE; ENDOMETRIOSIS; GROWTH; EXPRESSION; MUTATIONS; ARID1A; CARCINOGENESIS;
D O I：
10.1093/jjco/hyu221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed.
引用
收藏
页码：405 / 407
页数：3
相关论文
共 50 条
  • [31] Targeted Therapy in Ovarian Cancer
    Willmott, Lyndsay J.
    Fruehauf, John P.
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [32] OVARIAN-CARCINOMA - OLD PROBLEMS, NEW HOPES
    PFLEIDERER, A
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1991, 250 (1-4) : 64 - 71
  • [33] New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment-a narrative review
    Satora, Malgorzata
    Kulak, Krzysztof
    Zaremba, Bartlomiej
    Grunwald, Arkadiusz
    Swiechowska-Starek, Paulina
    Tarkowski, Rafal
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] ERK-binding protein PEA-15 modulates ERK-targeted therapy in ovarian clear cell carcinoma
    Oishi, Tetsuro
    Bartholomeusz, Chandra
    LaFortune, Tiffany
    Kazansky, Anna
    Zhang, Dongwei
    Itamochi, Hiroaki
    Ueno, Naoto
    CANCER RESEARCH, 2009, 69
  • [35] Osteopontin as a potential molecular target for ovarian clear cell carcinoma therapy.
    Matsuura, M.
    Suzuki, T.
    Tabuchi, Y.
    Habata, S.
    Tanigaki, E.
    Suzuki, M.
    Tanaka, R.
    Iwasaki, M.
    Hayakawa, O.
    Ito, E.
    Ebina, Y.
    Saito, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
    Loh, J.
    Ngoi, N. Y. L.
    Blanc-Durand, F.
    Ang, S. Y. R.
    Elias, E.
    Lai, A.
    Lim, D.
    Lim, Y. W.
    Lim, S. E.
    Low, J.
    Ng, J.
    Sundararajan, V.
    Thian, Y. L.
    Tong, P.
    Wijaya, S.
    Tan, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S532 - S533
  • [37] CANCER-ASSOCIATED GALACTOSYLTRANSFERASE AS A NEW TUMOR-MARKER FOR OVARIAN CLEAR CELL-CARCINOMA
    NOZAWA, S
    YAJIMA, M
    SAKUMA, T
    UDAGAWA, Y
    KIGUCHI, K
    SAKAYORI, M
    NARISAWA, S
    IIZUKA, R
    UEMURA, M
    CANCER RESEARCH, 1990, 50 (03) : 754 - 759
  • [38] Targeting STAT3 as a novel therapy for ovarian clear cell carcinoma
    Bixel, Kristin L.
    Saini, Uksha
    Fowler, Jack
    Rajendran, Sneja
    Wanner, Ross
    Matsumura, Noriomi
    Hideg, Kalman
    Konishi, Ikuo
    Cohn, David
    Karrupaiyah, Selvendiran
    CANCER RESEARCH, 2015, 75
  • [39] From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer
    Gomez-Raposo, Cesar
    Mendiola, Marta
    Barriuso, Jorge
    Hardisson, David
    Redondo, Andres
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (05) : 591 - 594
  • [40] Aptamers: ushering in new hopes in targeted glioblastoma therapy
    Chatterjee, Debarpan
    Bhattacharya, Srijan
    Kumari, Leena
    Datta, Aparna
    JOURNAL OF DRUG TARGETING, 2024,
12345